ACP says no need for pelvic exams

Share this article:

The American College of Physicians issued new guidelines that run smack up against those of the American College of Obstetrics and Gynecologists: women, it says, can eschew yearly pelvic exams.

The Wall Street Journal reports the ACP based its recommendations on data from 1946 through 2014 which indicated the exams are not a major help in detecting diseases such as ovarian cancer and have not reduced overall mortality. ACP also noted that the exams cause many women stress. “I think it's something women don't necessarily look forward to,” former ACP president Sandra Adamson Fryhofer told the New York Times.

The Times notes that while gynecologists “agree that pelvic exams are not good tools for screening for ovarian cancer... experienced physicians can use pelvic exams to find other problems, such as noncancerous fibroids” as well as changes associated with sexual dysfunction and incontinence. The Times also notes that these exams up the cost of a woman's office visit because it prolongs the time of the visit and often requires a chaperone in the room.

Mount Sinai assistant professor of obstetrics, gynecology and reproductive science Taraneh Shirazian told the Journal the exam should be part of an annual health review. “It may not be 100% sensitive, and it may not be able to pick up cancer of the ovary, but it gives us a baseline idea of the health,” she said.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.